These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7201887)

  • 21. Prostaglandin E1 in suspected ductus dependent cardiac malformation.
    Hallidie-Smith KA
    Arch Dis Child; 1984 Nov; 59(11):1020-6. PubMed ID: 6542338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostaglandin and damage to ductus arteriosus.
    Moulaert AJ; Gittenberger AC; Harinck E
    Lancet; 1977 Mar; 1(8013):703-4. PubMed ID: 66503
    [No Abstract]   [Full Text] [Related]  

  • 23. E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations.
    Olley PM; Coceani F; Bodach E
    Circulation; 1976 Apr; 53(4):728-31. PubMed ID: 56243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological manipulation of the ductus arteriosus.
    Silove ED
    Arch Dis Child; 1986 Sep; 61(9):827-9. PubMed ID: 3767410
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of ductus-dependent congenital heart diseases with prostaglandin E1].
    Lillquist K
    Ugeskr Laeger; 1979 Jul; 141(28):1915-6. PubMed ID: 473414
    [No Abstract]   [Full Text] [Related]  

  • 26. Alprostadil (Prostin VR Pediatric Sterile Solution, The Upjohn Company).
    Roehl SL; Townsend RJ
    Drug Intell Clin Pharm; 1982 Nov; 16(11):823-32. PubMed ID: 6756848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Skeletal side effects of treatment with prostaglandin E1].
    Persigehl M; Hövels-Gürich H; von Bernuth G
    Rofo; 1984 Oct; 141(4):427-30. PubMed ID: 6436918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comments on the pharmacologic manipulation of the ductus arteriosus in newborns.
    Rowe RD
    Adv Prostaglandin Thromboxane Res; 1978; 4():383-5. PubMed ID: 645513
    [No Abstract]   [Full Text] [Related]  

  • 29. Medical manipulation of the ductus arteriosus.
    Elliott RB; Starling MB; Neutze JM
    Lancet; 1975 Jan; 1(7899):140-2. PubMed ID: 46053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ductus arteriosus: why and how to manipulate its patency.
    Drummond WH; Bucciarelli RL; Gessner IH
    J Fla Med Assoc; 1983 Sep; 70(9):788-93. PubMed ID: 6355376
    [No Abstract]   [Full Text] [Related]  

  • 31. Congenital heart disease and respiratory distress syndrome. Reversal of indomethacin closure of patent ductus arteriosus by prostaglandin therapy in a preterm infant.
    Strauss A; Modanlou HD; Gyepes M; Wittner R
    Am J Dis Child; 1982 Oct; 136(10):934-6. PubMed ID: 6889810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of prostaglandin E1 infusion in the pre-operative management of critical congenital heart disease.
    Ohara T; Ogata H; Fujiyama J; Murata Y; Abe J; Kakuta K; Hayamizu S; Kameyama S; Yoshida Y
    Tohoku J Exp Med; 1985 Jun; 146(2):237-49. PubMed ID: 4040664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of prostaglandin in heart abnormalities with needed patency of the arterial canal (clinical and histological study)].
    Moulaert A; Gittenberger-De Groot A; Harinck E
    Arch Fr Pediatr; 1978; 35(7):717-25. PubMed ID: 736728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular therapy in the newborn.
    Sandor GG
    Clin Invest Med; 1985; 8(4):360-7. PubMed ID: 3907921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified Blalock-Taussig shunt following long-term administration of prostaglandin E1 for ductus-dependent neonates with cyanotic congenital heart disease.
    Yokota M; Muraoka R; Aoshima M; Nomoto S; Shiraishi Y; Kyoku I; Kitano M; Shimada I; Nakano H; Ueda K
    J Thorac Cardiovasc Surg; 1985 Sep; 90(3):399-403. PubMed ID: 4033176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letter: Medical manipulation of the ductus arteriosus.
    Christensen NC; Fabricus J
    Lancet; 1975 Aug; 2(7931):406-7. PubMed ID: 51207
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of prostaglandins in duct-dependent congenital heart conditions.
    Singh Y; Mikrou P
    Arch Dis Child Educ Pract Ed; 2018 Jun; 103(3):137-140. PubMed ID: 29162633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prolonged prostaglandin E-1 therapy of newborn infants with congenital heart defects].
    Kertész E; Hencz P; Tekulics P; Beviz J; Száva J; Matkó I; Kovács G
    Orv Hetil; 1980 May; 121(20):1197-9. PubMed ID: 7413203
    [No Abstract]   [Full Text] [Related]  

  • 39. [Prostaglandin E1 therapy in infants with cyanotic congenital heart malformations: hemodynamic and angiographic findings (author's transl)].
    Schumacher G; Mocellin R; Schöber JG; Kellner M; Bühlmeyer K
    Klin Padiatr; 1978 Sep; 190(5):465-73. PubMed ID: 568198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostaglandins and the ductus arteriosus.
    Olley PM; Coceani F
    Annu Rev Med; 1981; 32():375-85. PubMed ID: 7013675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.